Oyster Point Pharma, Inc. Email Format
Pharmaceutical ManufacturingNew Jersey, United States11-50 Employees
Oyster Point Pharma, Inc. is a commercial-stage biopharmaceutical company based in Princeton, New Jersey, focused on discovering, developing, and bringing to market innovative therapies for eye diseases. With a relatively small workforce, it operates within the pharmaceutical manufacturing sector, seeking to offer new options to patients with ophthalmic conditions. The company brought Tyrvaya to market in late 2021 as a nasal spray for dry eye disease, representing its first FDA-approved therapy. The product achieved formulary inclusion with Express Scripts, improving access for patients. In February 2023, Oyster Point Pharma announced the promotion of Amanda Leleszi from director of U.S. compliance and ethics to senior director.